| Similar Articles |
|---|
 |
Popular Mechanics
November 2009
Meigs & Beilinson |
Exclusive Interview With Inventor and Innovator Dean Kamen Dean Kamen has transformed medical technology and amassed more than 440 patents. And in his spare time he is remaking American culture, one future engineer at a time.   |
Pharmaceutical Executive
May 1, 2007
Humphrey Taylor |
Commentary: The Sky is Falling! Healthcare systems in the developed world are in crisis. A permanent one. Patients and their physicians will always want more treatments than governments or employers are willing to pay for. |
Pharmaceutical Executive
July 30, 2007
Peter Pitts |
Opinion: Fewer Cents, More Sense Our healthcare system may be broken, but playing the blame game is not going to fix it. Remember that disease - not Big Pharma - is the enemy. |
Pharmaceutical Executive
August 1, 2012
Carol Ann Williams |
Data Exclusivity: Making the Case As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine. |
HBS Working Knowledge
November 22, 2004
Martha Lagace |
Does the Medical Industry Deliver Value? When the discussion turns to healthcare reform, we get sidetracked on issues such as soaring costs. The real issue is, what is the most effective way to treat a disease or condition? |
Pharmaceutical Executive
October 1, 2011 |
The Legacy of High Expectations Andrew Witty, Chairman & CEO, GlaxoSmithKline, believes the pharmaceutical industry will continue to make a significant contribution to society if it continues to improve the way it goes about its work. |
Popular Mechanics
November 2009 |
The Adventures of Inventor Dean Kamen: Timeline A timeline on the life of Dean Kamen, from when he hacked his parents house to his invention of the Segway and a cheap system for purifying water. |
Pharmaceutical Executive
September 1, 2005
Wolfgang Klietmann |
Thought Leader: (Eco)systemic Change The author discusses how various players within the healthcare system interact. |
Financial Planning
April 1, 2010
Rick Kahler |
Healthcare on the Critical List Even if Congress does enact a new law, it seems that the same old problems will remain, at least for the next few years. So let's take a careful look at what's at stake. |
Knowledge@Wharton
August 27, 2003 |
Code Blue: Combating Rising Healthcare Costs Calls for Strong Medicine It's been said many times over that the U.S. healthcare industry is a sick patient in search of a cure. The metaphor is a grim reflection of how the country is coping with an aging population, rising costs and an inefficient healthcare delivery system. |
Pharmaceutical Executive
September 1, 2012
Robin Hertz |
The Endless Treadmill of End-of-Life Care Bending the cost curve back to valuing the cycle of life. |
HBS Working Knowledge
July 12, 2006
Roger Thompson |
Competition the Cure for Healthcare Michael Porter is considered by many the world's foremost authority on competition and strategy. So when he discusses the need for fundamental reform in the way the United States delivers healthcare, people listen. |
Pharmaceutical Executive
July 1, 2011 |
Holy Surge of Enthusiasm! While Europe's EFPIA preaches about embracing change, much remains to be done to prove the adjustment in philosophy. |
Pharmaceutical Executive
October 1, 2011 |
Regulation and Reputation: Still Two Solitudes The pharmaceutical and biopharmaceutical industries will only be able to continue providing patients with safe and effective medicines if the price is affordable. This will involve changes in attitudes by the industry, regulators, politicians, and the public. |
Pharmaceutical Executive
February 1, 2007
Humphrey Taylor |
Opinion: Myth vs. Reality The debate about reform of the American healthcare system has been ideologically driven rather than evidence-based. Here, we separate myth from reality. |
Investment Advisor
May 2010
Ron Pechtimaldjian |
Tax Implications Taxes are, for a change, probably the easiest area to consider when assessing the implications of healthcare reform for advisors and their clients. |
Financial Planning
February 1, 2005
Neil A. O'Hara |
The Harvest to Come Pharmaceutical stocks may be down, but they're hardly out. For planners and clients who can tolerate the risk of concentration, a selective allocation to the healthcare industry today may represent the ability to buy growth at a value price. |
Information Today
October 29, 2015 |
Thomson Reuters Streamlines Healthcare Industry Analysis Thomson Reuters rolled out the Healthcare Intelligence application for Thomson Reuters Eikon to improve workflow for financial professionals. |
Salon.com
October 16, 2000
Beatrice Motamedi |
America's sick healthcare system A compelling PBS documentary explores the mess that Al Gore and George W. Bush refuse to confront... |
Pharmaceutical Executive
November 1, 2008
Patrick Clinton |
Pharm Exec Q&A: Tommy Thompson The former health secretary offers a reality check on healthcare reform and what to expect in '09. |
Pharmaceutical Executive
May 1, 2005
Marsha Meyer |
Medical Education: Prevention Education Shifting the nation's healthcare paradigm from treating seniors' ills to preventing them will take the combined support of pharma companies, medical schools, continuing medical education (CME) providers, and clinicians. |
Chemistry World
March 25, 2010
Rebecca Trager |
Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'. |
Wired
September 2000
Scott Kirsner |
Breakout Artist Dean Kamen, multimillionaire inventrepreneur, is going global with a robochair that climbs stairs, a miracle motor that fights disease, and his wildest notion of all - that scientists will be the 21st century's superstars. |
Pharmaceutical Executive
October 1, 2012
Nicolas Pechet |
Your Local Competitor: A Threat in Emerging Markets? Pharmaceutical companies looking to wrest market share in high growth markets of tomorrow must overcome challenges from a new crop of national champions. |
Pharmaceutical Executive
May 6, 2014
Adjei et al. |
Africa: The Lost Continent No More Driven by a rising GDP and calmer political and financial waters over the past decade, Africa's nascent healthcare sector is poised for a fresh surge in growth. |
HBS Working Knowledge
November 17, 2003
Martha Lagace |
Curbing the Costs of Disease Runaway healthcare costs are driven by multiple symptoms. A conference panel tells how the industry as a whole can get better treatment. |
Pharmaceutical Executive
April 1, 2007
Humphrey Taylor |
Opinion: Inappropriate Behavior Do doctors prescribe needless care? Will healthcare costs drop if patients decide whether treatment is necessary? It's time to start talking. |
IEEE Spectrum
February 2008
Sarah Adee |
Dean Kamen's Luke Arm Prosthesis Readies for Clinical Trials DARPA may decide the fate of Dean Kamen's next-generation prosthetic arm. |
Financial Planning
February 1, 2006
Marie F. Smith |
AARP's Blueprint Americans can -- and should -- pull together to create a secure future for its citizens. To suggest that an older America will precipitate a crisis overstates the problem and fails to consider some major mitigating factors. |
The Motley Fool
May 20, 2011
Arlene Weintrab. |
Miller Tabak Fund Manager Says Investors Are Ignoring the Upsides in Healthcare This manager says investors in 2013 are going to look back and wish they had invested more in healthcare funds today. |
CRM
September 24, 2004
Jason Compton |
Vertical Focus: Healthcare Organizations Turn to CRM to Cure Their Ailing Customer Strategies The industry feels the same pressure as other markets do to do more with less. |
HBS Working Knowledge
November 17, 2003
Martha Lagace |
The Business Case for Diabetes Disease Management Diabetes is a tough disease to tackle. A case-study discussion led by Harvard professor Nancy Beaulieu asked why it is so complex for business and society, and what might be done to curb its incidence. |
Pharmaceutical Executive
August 1, 2012
Pascheles & Bogan |
The Ultimate Business Model: Planning that Thousand Year Future In an era where success is monitored and measured in microseconds, planning for the long term is increasingly seen as an abstract absurdity. Yet the principles of natural selection, when applied to the pharmaceutical business, suggest that a lasting business model is still possible. |
Investment Advisor
April 2010
Vaughan Scully |
The ETF Advisor: Prospects for Healthcare ETFs Better Than Those for Reform There are about two dozen exchange traded funds that offer a wide variety of exposures to the healthcare sector, including broad-based, global, and leveraged ETFs, as well as those targeting individual industries. |
Insurance & Technology
May 18, 2004
Lisa Valentine |
Affordability and Service Oxford Health Plans' CIO Steve Black believes a sweet spot exists between high-tech and high-touch. |
Nursing Management
January 2012
Lawrence et al. |
Type 2 Diabetes: Growing to Epic Proportions Affecting all age groups and all aspects of a person's life, diabetes is a major public health issue worldwide, requiring lifelong behavioral and lifestyle changes and support. |
CRM
June 2011
Koa Beck |
Can Mobile Help Clarify Confusion Over Reforms? Healthcare reform has thrown everything up for question. |
Financial Planning
April 1, 2008
David E. Adler |
Your Retiring Clients' Biggest Fear How to pay for healthcare is the single biggest concern that people have approaching retirement. It's important for planners to understand this as well; not only for clients, but for themselves. |
Managed Care
February 2001
Michael S. Victoroff |
Helping Patients Make Informed Decisions Now Harder Thanks to Range of Treatment The duty of informed consent necessitates that physicians discuss with their patients the realistic expectations and risks associated with treatment. When no protocol shows a distinct advantage, there is no duty to inform, which creates an ethical problem for physicians... |
Financial Planning
April 1, 2006
Donald Jay Korn |
Rx for Investing Healthcare stocks may cure investors' ills over the long term, but the current prognosis is less clear. For clients in diversified funds, planners should decide whether additional healthcare exposure is justified, through individual stocks or specialized funds. |
Pharmaceutical Executive
January 1, 2012
Elys Roberts & Sarah Phillips |
The Emergence of the Pro-Patient How can pharma embrace and interact with increasingly informed and demanding patients to bring positive outcomes for all? |
Pharmaceutical Executive
July 1, 2011
Mangesh Sai |
What the 2011 Census of India Reveals for Pharma What India's latest census tells us about current and future pharma opportunities. |
Pharmaceutical Executive
June 1, 2011 |
Are You Ready for the New China? The ability to act as a good corporate citizen and assert a useful role in national industrial policy on health is going to be essential to success in the new China. |
Investment Advisor
July 2009
Melanie Waddell |
The Great Health Reform Debate President Barack Obama has set an ambitious deadline of October to achieve comprehensive healthcare reform. |
